2023
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314
Lu Y, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Meeks J, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. European Urology Oncology 2023, 6: 516-524. PMID: 37087309, PMCID: PMC10587361, DOI: 10.1016/j.euo.2023.03.008.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerNeoadjuvant chemotherapyCooperative group trialsCell-free DNA methylationProspective cooperative group trialsPathologic responseBladder cancerRadical cystectomyNAC responseChemotherapy responseTreatment responseGroup trialsCycles of chemotherapyNeoadjuvant chemotherapy responseAdvanced bladder cancerStandard of careBladder cancer patientsIndependent predictive abilityGene expression signaturesMetastatic diseaseCancer patientsPredictive biomarkersPathologic respondersCurrent exploratory analysisInvasive approach
2022
Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma
Chen X, Chen H, Lin R, Li Y, Guo Y, Chen Q, Zhang Y, Cai G, Hu M, Chen G. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma. Journal Of Clinical Pathology 2022, 77: 61-67. PMID: 36319076, PMCID: PMC10804014, DOI: 10.1136/jcp-2021-207795.Peer-Reviewed Original ResearchPD-L1 expressionUrothelial carcinomaOverall survivalPD-L1Tumor cellsCell infiltrationInvasive frontPD-1/PD-L1 signal pathwayNon-small cell lung cancerOS of patientsInvasive bladder urothelial carcinomaPD-L1 groupIndependent prognostic factorT cell infiltrationAdvanced bladder cancerCell lung cancerImmune cell infiltrationMore T cellsFirst new drugT cell functionBladder urothelial carcinomaMeans of immunohistochemistryLymphocyte infiltrationPD-1Prognostic factors
2020
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel V, Oh W, Galsky M. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA A Cancer Journal For Clinicians 2020, 70: 404-423. PMID: 32767764, DOI: 10.3322/caac.21631.Peer-Reviewed Original ResearchConceptsAdvanced bladder cancerCharacterization of bladder cancerBladder cancerMuscle-invasiveGenomic characterization of bladder cancerMolecular characterization of bladder cancerManagement of muscle-invasiveTreatment of muscle-invasiveMuscle-invasive bladder cancerFibroblast growth factor receptor inhibitorGrowth factor receptor inhibitorsCharacteristics of bladder cancerImmune checkpoint inhibitorsMolecular characteristics of bladder cancerPlatinum-based chemotherapyDevelopment of novel therapiesBladder cancer managementChanging treatment landscapeOptimal treatment approachPotential therapeutic vulnerabilitiesAntibody-drug conjugatesBladder cancer pathogenesisCheckpoint inhibitorsMutational burdenReceptor inhibitors
2016
Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer
Galsky M, Stensland K, Moshier E, Sfakianos J, McBride R, Tsao C, Casey M, Boffetta P, Oh W, Mazumdar M, Wisnivesky J. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. Journal Of Clinical Oncology 2016, 34: 825-832. PMID: 26786930, DOI: 10.1200/jco.2015.64.1076.Peer-Reviewed Original ResearchConceptsLocally advanced bladder cancerEffect of adjuvant chemotherapyAdjuvant chemotherapyBladder cancerOverall survivalPerformance statusImproved survivalNode-positive bladder cancerNational Cancer Data BaseAssociated with improved survivalObservational studyEffect of cystectomyTumor-level characteristicsImpact of performance statusPositive surgical marginsChemotherapy-treated patientsCompare overall survivalLymph node involvementAdvanced bladder cancerPoor performance statusLevel I evidencePropensity scoreReal-world patientsStudy inclusion criteriaPathological T3
2015
First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.
Bellmunt J, Eigl B, Senkus-Konefka E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar S, Sternberg C, Retz M, Blumenstein B, Jacobs C, Stewart P, Petrylak D. First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. Journal Of Clinical Oncology 2015, 33: 4503-4503. DOI: 10.1200/jco.2015.33.15_suppl.4503.Peer-Reviewed Original Research
2014
Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice
Tan W, Lamb B, Payne H, Hughes S, Green J, Lane T, Adshead J, Boustead G, Vasdev N. Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. Clinical Genitourinary Cancer 2014, 13: e153-e158. PMID: 25510376, DOI: 10.1016/j.clgc.2014.11.006.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapy regimenNeoadjuvant chemotherapyPositive lymph nodesRadical cystectomyAdjuvant chemotherapyTreatment of patientsBladder cancerNodal diseaseLymph nodesIndication of adjuvant chemotherapyNode-positive bladder cancerPresence of disease progressionResponse to NACCancer CenterMuscle-invasive bladder cancerCycles of gemcitabineAdvanced bladder cancerPatient performance statusUro-oncologistsChemotherapy regimenPerformance statusLack of published evidenceDisease progressionChemotherapyPatients
2012
Safety, pharmacokinetics, and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors.
Haluska P, Menefee M, Plimack E, Rosenberg J, Northfelt D, LaVallee T, Huang W, Yu X, Viner J, LoRusso P. Safety, pharmacokinetics, and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors. Journal Of Clinical Oncology 2012, 30: tps2618-tps2618. DOI: 10.1200/jco.2012.30.15_suppl.tps2618.Peer-Reviewed Original ResearchMEDI-573Advanced solid tumorsSolid tumorsAdult patientsGlucose homeostasisDose levelsDrug-related adverse eventsMedian age 64 yearsAdequate organ functionIGF-I/-IIInvestigational monoclonal antibodyAntitumor activityAcceptable safety profileAdvanced bladder cancerAge 64 yearsKarnofsky statusQ3W dosingStable diseaseAdverse eventsSafety profileIGF-IIBladder cancerSerum glucoseSerious toxicityIGF-1R
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply